Absci Corporation, trading on the Nasdaq under the symbol ABSI, is a clinical-stage biopharmaceutical company. It focuses on developing breakthrough therapeutics using generative AI. The company is set to participate in the 44th Annual J.P. Morgan Healthcare Conference, showcasing its commitment to advancing drug discovery.
On December 17, 2025, H.C. Wainwright set a price target of $8 for ABSI. At that time, the stock was priced at $3.44, suggesting a potential increase of about 67.77%. Currently, the stock is priced at $3.39, reflecting a slight decrease of 4.38% from the previous price, with a change of $0.16.
ABSI's stock has shown volatility, with a daily range between $3.38 and $3.64. Over the past year, it has fluctuated significantly, reaching a high of $6.33 and a low of $2.01. This volatility is common in clinical-stage biopharmaceutical companies due to the inherent risks and uncertainties in drug development.
Absci's market capitalization is approximately $510.4 million, indicating the total market value of its outstanding shares. The trading volume on the NASDAQ exchange is 1,986,998 shares, reflecting investor interest and activity in the stock. The company's innovative approach in drug discovery, combining AI and synthetic biology, positions it as a notable player in the biopharmaceutical industry.
